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OPEN
REVIEW
Immune checkpoint inhibition: prospects for
prevention and therapy of hepatocellular carcinoma
Caryn L Elsegood1, Janina EE Tirnitz-Parker1, John K Olynyk1,2,3 and George CT Yeoh4,5
The global prevalence of liver cancer is rapidly rising, mostly as a result of the amplified incidence rates of viral hepatitis,
alcohol abuse and obesity in recent decades. Treatment options for liver cancer are remarkably limited with sorafenib being the
gold standard for advanced, unresectable hepatocellular carcinoma but offering extremely limited improvement of survival time.
The immune system is now recognised as a key regulator of cancer development through its ability to protect against infection
and chronic inflammation, which promote cancer development, and eliminate tumour cells when present. However, the
tolerogenic nature of the liver means that the immune response to infection, chronic inflammation and tumour cells within the
hepatic environment is usually ineffective. Here we review the roles that immune cells and cytokines have in the development of
the most common primary liver cancer, hepatocellular carcinoma (HCC). We then examine how the immune system may be
subverted throughout the stages of HCC development, particularly with respect to immune inhibitory molecules, also known as
immune checkpoints, such as programmed cell death protein-1, programmed cell death 1 ligand 1 and cytotoxic T lymphocyte
antigen 4, which have become therapeutic targets. Finally, we assess preclinical and clinical studies where immune checkpoint
inhibitors have been used to modify disease during the carcinogenic process. In conclusion, inhibitory molecule-based
immunotherapy for HCC is in its infancy and further detailed research in relevant in vivo models is required before its full
potential can be realised.
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INTRODUCTION
Primary liver cancer is the sixth most prevalent cancer globally, but
importantly the second most common cause of cancer-related death
due to limited treatment options.1 The risk of adult primary liver
cancer is considerably enhanced by cirrhosis resulting from viral
hepatitis (hepatitis B virus (HBV) and hepatitis C virus (HCV)),
alcohol, obesity, metabolic liver diseases and aflatoxin exposure.
Paediatric primary liver cancer generally results from genetic condi-
tions, such as Beckwith–Wiedemann syndrome, hemihypertrophy and
familial adenomatous polyposis, and inborn metabolic errors, such as
tyrosinaemia, alpha-1 antitrypsin deficiency and glycogen storage
disease type 1. Resection and percutaneous local ablation are the only
treatment options for early-stage tumours. Repeated transarterial
chemoembolisation is used for intermediate stage, while oral sorafenib
is the gold-standard treatment for advanced hepatocellular carcinoma
(HCC) with only modest improved survival time.2 Thus it is
imperative that new alternatives are developed to limit liver cancer
development or to treat advanced liver cancer.
HCC, cholangiocarcinoma (or bile duct cancer), primary hepatic
angiosarcoma and hepatoblastoma represent the four main subtypes of
primary liver cancer. Rare variants are tumours with combined
hepatocellular and cholangiocellular features, referred to as a mixed
hepatocellular cholangiocarcinoma.3 HCC is the most studied subtype
and accounts for 85–90% of all primary liver cancers. There is
evidence to support its origin from hepatocytes or a liver stem/
progenitor cell in both adults and children.4 Cholangiocarcinoma is a
heterogeneous malignancy that develops in the biliary tree of adults
and is classified as intrahepatic, perihilar or distal based on the
anatomical location.5 Primary hepatic angiosarcoma is an extremely
rare soft tissue sarcoma in which pleomorphic endothelial cells grow
into vascular spaces, including sinusoids and terminal hepatic
venules.6 Hepatoblastoma is similarly a very rare paediatric primary
liver cancer thought to arise from a hepatocyte precursor known as a
hepatoblast, which is present during fetal liver development.7
The original six hallmark features of cancer focussed on tumour cell
features that enabled survival, proliferation and dissemination.8
Importantly, the immune system has now also been recognised to
be central to tumorigenesis in an expanded roster of hallmarks of
cancer.8 Accordingly, a number of strategies to inhibit carcinogenesis
are being developed, which target distinct immunological
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mechanisms.9 The immune system can (i) suppress viral-induced
tumours by protecting the host against infection,9 (ii) prevent
establishment of a chronic inflammatory environment that promotes
cancer by inducing genetic instability and mutation in target cells9,10
and (iii) eliminate tumour cells that often co-express ligands for
activating innate immune cell receptors and tumour antigens that are
recognised by lymphocyte receptors.9 However, importantly, the
tolerogenic nature of the liver presents unique and specific challenges
to suppressing hepatic tumour development.
Oncolytic immunotherapy has been explored in many types of
tumours. Immunotherapy for HCC, though, is relatively under-
explored. Interleukin-12 (IL-12) cytokine administration and IL-12-
based gene and cell-based therapies have been used to treat HCC in
preclinical studies.11–13 Granulocyte macrophage colony-stimulating
factor-based gene therapy has been used to successfully reduce tumour
burden in HCC patients.14 However, it is unclear if the efficacy was
due to immune- or viral-based oncolysis. Adoptive transfer of
chimeric antigen receptor-modified T cells is presently being examined
as a possible therapeutic for HCC.15 There is similarly much
excitement with the advent of monoclonal antibody-based therapy
to block immune-inhibitory molecules, such as programmed cell
death protein-1 (PD-1), programmed cell death 1 ligand 1 (PDL-1)
and cytotoxic T lymphocyte antigen 4 (CTLA4), which prevent T cells
from killing tumour cells. This therapy is now widely used in the clinic
to treat solid tumour melanoma16 and is in the early stages of
evaluation in the setting of HCC. Importantly, the immune response
to blocking of inhibitory molecules can be sustained beyond the
prescribed treatment duration.
In this review, we will explore how the immune system regulates the
development of the most common liver cancer, HCC, with a focus on
the inhibitory receptors known as immune checkpoint inhibitors. We
will first review the T-cell subsets present in the liver together with
basic concepts of T-cell activation, differentiation and exhaustion. We
will briefly discuss mechanisms that contribute to hepatic immune
tolerance as well as cytokines that regulate the tolerance. Immune
inhibitory molecules have primarily been viewed as agents that inhibit
immune responses to tumour cells. However, it is now apparent that
their expression is also upregulated during viral infection and chronic
inflammation. Thus we will focus on how viral hepatitis, chronic
inflammation and HCC use the inhibitory molecules to subvert the
immune system’s ability to prevent hepatic carcinogenesis. Finally, we
will explore how the new inhibitory molecule-based immunotherapies
may be utilised to prevent HCC development or treat advanced HCC.
IMMUNE CELLS AND CYTOKINES INVOLVED IN HCC
DEVELOPMENT
The immune system has a central role in the progression of chronic
liver disease and HCC development with the relative contributions
and responses of regulatory, helper and cytotoxic effector T cells
central to determining whether chronic liver disease progresses to
HCC. In particular, cytotoxic T cells are essential for targeting and
destroying infected or tumorigenic hepatic cells while regulatory
T cells dampen cytotoxic T-cell responses. The T-cell subsets present
are determined by contextual information such as the cytokine milieu
and strength of antigen stimulation. Below, we examine the key basic
concepts of T-cell biology and cytokine regulation of hepatic tolerance
that are important for HCC development.
T-cell activation and differentiation
Naive T cells activate and clonally expand in response to antigen-
presenting cell (APC)-expressed major histocompatibility complex
(MHC)-I or MHC-II binding to the T-cell receptor (TCR) of CD8+ or
CD4+ T cells, respectively. In general, the clonally expanded CD4+
T cells differentiate into regulatory and helper T-cell subsets in
response to the cytokines they are exposed to and as defined by their
transcription factor expression and cytokine secretion. The most
common hepatic CD4+ T-cell subsets are T helper type 1 (Th1),
Th2, Th9 and Th17 helper T cell and regulatory T cells (Tregs) subsets.
CD8+ T cells differentiate into cytotoxic T cells and subsequently into
memory T cells. The cytokine combinations that induce each subset
in vitro, together with the master transcription factor expressed,
characteristic cytokines secreted and global function(s) of each T-cell
subset, are described below.
Th1 cells. IL-12 together with interferon (IFN)-γ induce naive
CD4+ T cells to differentiate into Th1 cells, which express the T-bet
transcription factor and secrete IFN-γ and tumour necrosis factor
(TNF).17,18 Th1 cells promote cell-mediated immunity and activate
clearance of tumour cells and intracellular pathogens as a result of
production of the pro-inflammatory cytokines.17
Th2 cells. Th2 cells are produced from naive CD4
+ T cells in response
to IL-4 and IL-33, express GATA-3 transcription factor and secrete
IL-4, IL-5, IL-10, IL-13 and IL-25.17,18 Th2 cells suppress Th1-driven
inflammation and associated tissue damage and remove extracellular
parasites such as helminths and Schistosoma as a result of recruitment
of eosinophils, mast cells and basophils.17
Th9 cells. Th9 cells are produced from naive CD4
+ T cells by
stimulation with transforming growth factor (TGF)-β together with
IL-4, express PU.1 transcription factor and secrete IL-9 and IL-10.18
Th9 cells promote Th2 responses in murine atopic diseases, are pro-
inflammatory in ulcerative colitis and antitumoral in solid tumour
models.18 Peripheral blood Th9 cell numbers are elevated in cirrhotic
patients and are positively associated with the severity of cirrhosis.19
However, the nature of the Th9 cells’ role in chronic liver disease
remains undetermined.
Th17 cells. Th17 cells are produced from naive CD4
+ T cells in the
presence of TGF-β together with IL-6 and IL-21 in mice or IL-23 in
humans.18 Th17 cells express retinoic acid–related orphan receptor γt
transcription factor and produce IL-17, IL-21, IL-22 and TNF. IL-17
promotes endothelial cell expression of granulocyte macrophage
colony-stimulating factor (or colony-stimulating factor-2) and/or
granulocyte colony stimulating factor (or colony-stimulating
factor-3) and thus inflammatory neutrophil and monocyte
recruitment.20 Th17 cells may have a critical role in the development
of liver diseases such as viral hepatitis and alcoholic liver disease as
well as HCC where their numbers correlate with angiogenesis and
poor prognosis.21,22 Indeed, IL-17 mediates the spontaneous HCC that
develops by 65 weeks of age in mice expressing human unconven-
tional prefoldin RPB5 interactor (URI) in hepatocytes.23 However,
similar to Th9 cells, Th17 cells’ role is yet to be determined. Th17 cells
are also important for clearance of extracellular bacteria and fungi.17
Regulatory T cells. IL-2 in concert with TGF-β induces naive CD4+
T-cell differentiation to Tregs in vitro.
17 Tregs express the Foxp3
transcription factor and secrete IL-10 and TGF-β, which both suppress
the inflammatory functions of monocytes, macrophages, dendritic
cells (DCs) and B cells.24 Tregs also promote further differentiation of
naive CD4+ T cells to Tregs as a result of TGF-β production.
Importantly, Tregs maintain homeostasis and immune tolerance.
25
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However, an overabundance of Tregs promotes an immunosuppressive
environment.24
Tregs may be derived in vivo from naive CD4
+ T cells either in the
thymus (thymus-derived Tregs) or in peripheral tissues, such as lymph
nodes, spleen and liver (peripheral-derived Tregs). The definitive origin
of Tregs in the peripheral tissues including liver can, however, not be
ascertained owing to the current lack of defining markers.26 Thus, in
this review, we will refer to them collectively as Tregs.
Cytotoxic and memory CD8+ T cells. Naive CD8+ T cells clonally
expand in response to IL-12, or type I IFNs (IFN-α, IFN-β).27
Cytotoxic T-cell numbers then diminish during clearance of the
infection, and the remaining cells mature into memory CD8+ T cells.
IL-7 and IL-15 maintain memory T-cell numbers in the absence of
antigen.28 Cytotoxic antigen-specific CD8+ T cells express TNF, IFN-γ,
Fas ligand, granzyme B and perforin and kill virus-harbouring or
cancer cells expressing a specific antigen. In vivo, optimal CD8+ T-cell
function usually requires help from CD4+ T cells, including Th1 cells,
in the form of regulatory cytokines (for example, IL-21) and
chemokines as well as activating DCs via CD40:CD40 ligand
interactions.27,29 Thus the absence of CD4+ T cells results in defective
CD8+ T-cell production, reduced CD8+ memory cells and the inability
to mount a vigorous secondary immunogenic response.30
Regulation of T-cell activation strength
The strength of T-cell activation is controlled by the amount of
antigen presented to the TCR and by positive and negative co-
receptors. The most commonly described APC-expressed co-stimula-
tory receptors are CD80 (or B7-1) and CD86 (or B7-2), which engage
T cell-expressed CD28 to induce T-cell activation, as a result of T-cell
survival promoted by autocrine IL-2 signalling (Figure 1a).31 The
functions of other co-stimulatory receptors have recently been
reviewed extensively by Chen and Flies.31
Activation of the TCR is diminished by APC-expressed co-
inhibitory receptors such as PD-L1 (or B7-H1 or CD274) and PD-
L2 (or B7-DC or CD273), which both interact with T cell-expressed
PD-1 (or CD279) and dephosphorylate the TCR (Figure 1b). Further,
T-cell activation can be downregulated by APC-expressed CD80
binding to CTLA4 or CD152, which outcompetes costimulatory
CD28 for binding to APC-expressed CD80 as a consequence of higher
binding affinity (Figure 1c). APC-expressed PD-L1 binding to T-cell-
expressed CD80 and APC-expressed CD80 binding to T-cell-expressed
PD-L1 also attenuates T-cell activation although the precise mechan-
ism is unknown.32 Further, APC-expressed galectin 9 and MHC-I/
MHC-II can bind to T-cell-expressed T-cell immunoglobulin and
mucin-domain containing-3 (Tim-3) and lymphocyte-activation gene
3 (Lag-3/CD223), respectively, to attenuate T-cell activation. Other
inhibitory receptors have also recently been reviewed by Chen and
Flies.31
T-cell exhaustion
T-cell exhaustion has been described for both CD4+ and CD8+ T-cell
populations and occurs in response to persistent antigen exposure
and/or inflammation. Exhausted T cells have sustained expression of
co-inhibitory receptors, reduced effector function and an altered
transcriptional state compared with functional effector or memory T
cells.33 Importantly, exhausted T cells cannot mature into memory
T cells. T-cell exhaustion is characteristic of chronic viral infection and
tumorigenesis.
Induction of T-cell exhaustion. A key feature of T-cell exhaustion is
the chronic exposure of the TCR to antigen, with the extent of
exhaustion correlating with the level and duration of antigen exposure.
Inhibitory receptor signalling through PD-1 also downregulates T-cell
activation.34 Another contributing factor to CD8+ T-cell exhaustion
may be CD4+ Thelper cell exhaustion with concomitant enhanced IL-10
and IL-21 secretion.35
T-cell exhaustion is a stepwise process where the ability of the
T cells to produce IL-2 and proliferate is affected first, followed by
TNF secretion in the intermediate stages, with IFN-γ secretion most
resistant to inactivation.33 At the same time, there is a progressive
increase in the number and expression levels of co-inhibitory receptors
such as PD-1, CTLA4 and LAG3, over and above the levels induced
during differentiation, in addition to altered transcription factor
expression. In the final phase, the antigen-specific T cell can be
deleted. Importantly, it is now widely appreciated that exhausted
T cells are distinct from memory T cells and require antigen for
survival. Exhausted T cells are refractory to IL-7 and IL-15, which
promote memory T-cell survival.33 For further extensive review of the
T-cell exhaustion process, please see Wherry and Kurachi.36
Reversal of T-cell exhaustion. T-cell exhaustion can be reversed by
antibody neutralisation of the co-inhibitory receptors known uni-
versally as immune checkpoint inhibitors and that reduce T-cell
activation. Neutralising antibody blockade of PD-1 or PD-L1 in the
chronic murine lymphocytic choriomeningitis virus (LCMV) infection
model established that it was possible to reverse T-cell exhaustion.37
Specifically, PD-1 blockade increased proliferation, cytokine produc-
tion and cytolytic activity of hepatic and splenic CD8+ cytotoxic T cells
in chronic murine LCMV infection resulting in reduced viral titre.
Increased efficacy of treatment can be gained by combining blockade
of PD-L1 and other inhibitory molecules, such as Lag-3 and
Tim-3.38,39
Blockade of inhibitory molecules has also been combined with
therapies directed at extrinsic pathways, including IL-2 or IL-10. IL-2
administration synergises with PD-L1 blockade to enhance virus-
specific CD8+ T-cell responses and reduce viral titre in the chronic
LCMV infection mode despite a concomitant increase in
Treg numbers.
40 IL-10 can upregulate PD-L1 expression, and blockade
of both IL-10 signalling and PD-L1 can also synergistically enhance
cytotoxic CD8+ T-cell expression of IFN-γ and TNF and likewise
reduce LCMV viral titre.41 Additionally, Treg-depletion synergises with
PD-1 or Tim-3 blockade to augment CD8+ T-cell responses in the
murine Friend Virus model.42,43 These first successful attempts at
combined therapies in preclinical hepatic viral models highlighted
their potential clinical value in a patient setting.
Hepatic tolerance and T-cell regulation
The liver is the only non-lymphoid tissue in which naive CD4+ and
CD8+ T cells produced in the thymus can be activated independently
of the spleen and lymph nodes.44,45 Naive CD4+ and CD8+ T cells are
activated in the liver by non-conventional APCs in addition to DCs.46
Non-conventional hepatic APCs expressing MHC-I and MHC-II
include Kupffer cells (KCs or resident macrophages), liver sinusoidal
endothelial cells (LSECs) and hepatic stellate cells.47 Hepatocytes can
also cross-present antigen but only to CD8+ T cells as they express
MHC-I and not MHC-II.47 Hepatic stellate cells, though, may present
the antigen via transfer to LSECs in a process akin to trogocytosis, the
process of intercellular plasma membrane protein exchange.48
Under homeostatic conditions, the liver is continuously exposed to
harmless blood-borne non-self antigens originating from dietary
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nutrients, intestinal commensals and cellular debris. Thus specialised
mechanisms must be used to maintain hepatic tolerance. Conven-
tional and non-conventional APCs in the liver typically express low
levels of MHC molecules as well as CD80 and CD86 and are
accordingly weak T-cell activators.49 KCs are key regulators of
tolerance through their ability to produce heightened amounts of
IL-10 in response to lipopolysaccharide that then downregulates
expression of MHC molecules, CD80 and CD86 by the other
APCs.50,51 Additionally, hepatic DCs differ from other tissue DCs in
that they also produce elevated amounts of IL-10.52 Naive CD8+
T cells also promote PD-L1 expression by LSECs, which in turn
suppresses IL-2 production by CD8+ T cells.53 LSECs indirectly
promote tolerance by reducing DC expression of co-stimulatory
molecules and IL-12 in a process known as ‘vetoeing’.54 Thus
homeostatic hepatic-naive T-cell activation is low, resulting in
tolerance.
Cytokine regulation of hepatic tolerance. Hepatic tolerance and break-
ing of tolerance (or hepatic immunity) is also modulated by
microenvironment factors produced by surrounding APCs and
T cells themselves, including anti- and pro-inflammatory cytokines,
such as IL-10, TGF-β, IFN-γ and TNF. IL-10 induces tolerance via
effects on T cells and dampening inflammatory responses. TGF-β is a
key cytokine in maintenance of immune homeostasis or tolerance, but
elevated levels can promote detrimental tolerance or immunosuppres-
sion in the context of tumour cell immune surveillance. IFN-γ and
TNF are both thought to break immune tolerance, although chronic
exposure to TNF may induce immunosuppression. The effects of these
cytokines on hepatic tolerance are briefly discussed below.
Interleukin-10. Hepatic IL-10, produced by KCs, DCs, LSECs,
hepatic stellate cells, T cells55 and tumour-induced myeloid-derived
suppressor cells directly and indirectly promotes hepatic tolerance.56
IL-10 directly inhibits CD4+ T-cell activation and thus reduces effector
T-cell numbers57 and DC-primed cytotoxic CD8+ T-cell function.29
Hepatic T-cell activation is also indirectly reduced by IL-10 as a result
of downregulation of MHC-II and co-stimulatory CD80/CD86
molecules on KCs and LSECs with a subsequent reduction of their
T-cell stimulatory capacity.58 Further, IL-10 downregulates nuclear
factor-κB activity with concomitant reduction of inflammatory
cytokines, including TNF, IL-6, IL-8 and IL-12, and thus alleviates
T-cell activation.59
Figure 1 (a) T-cell activation is promoted by antigen presented to the TCR by APC-expressed MHC. The strength of T-cell activation is enhanced by APC-
expressed CD80 or CD86 binding to T cell-expressed CD28. TCR and CD28 downstream signalling promote nuclear factor (NF)-activated T cells (NFAT) and
NF-κB nuclear relocation, respectively, which synergise to promote IL-2 production and T-cell survival by IL-2 autocrine signalling to the IL-2R. (b) T-cell
activation strength is diminished by APC-expressed PD-L1 or PD-L2 binding to T-cell-expressed PD-1 to promote dephosphorylation of the TCR and reduce
TCR downstream signalling and IL-2 production. (c) T-cell-expressed CTLA4 binds to APC-expressed CD80 with higher affinity than CD28 and attenuates
CD28 downstream signalling and IL-2 production. JAK, Janus-activated kinase.
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Transforming growth factor-β. Hepatic TGF-β, produced by KCs,
DCs, LSECs, hepatic stellate cells, Tregs, natural killer (NK) T cells and
myeloid-derived suppressor cells also promotes hepatic tolerance.60
TGF-β is critical for naive CD4+ T-cell differentiation to Tregs and
inhibits differentiation of naive CD4+ T cells to pro-inflammatory Th1
and Th2 T-cell subsets as a result of inhibiting expression of the Th1
and Th2 essential transcription factors, T-bet and GATA3,
respectively.61,62 Additionally, TGF-β inhibits differentiation of naive
CD8+ T cells to cytotoxic CD8+ T cells independently of Smad3.63,64
Further, TGF-β inhibits cytotoxic CD8+ T-cell activity as a result of
inhibition of perforin and IFN-γ expression.65
Interferon-γ. The primary sources of IFN-γ in the liver are NK cells,
CD4+ Th1, cytotoxic CD8
+ T cells and NKT cells.66 IFN-γ secretion by
NK and T cells is promoted by IL-12, IL-18 and IFN-γ itself in a
feedforward loop, but production in NKT cells is independent of
cytokine signalling.
IFN-γ is required for Th1 immunity as it induces expression of the
Th1 master transcription factor, T-bet, resulting in naive CD4
+ T-cell
differentiation to Th1 cells. In vitro, IFN-γ inhibits differentiation of
Th2 and Th17 subsets. However, paradoxically, Th1 and Th17 cells are
often found in close association in pathology. In vivo, Th1 cell
production of IFN-γ can trigger myeloid APC production of IL-1
and IL-23 that promote Th17 differentiation, at least in psoriasis.
67
IFN-γ also activates innate immune cells such monocytes, macro-
phages and neutrophils to break tolerance and enhance antiviral
effects. IFN-γ promotes M1 macrophage polarisation and boosts
innate immune cell production of reactive oxygen species by enhan-
cing the expression of nitric oxide synthase 2, nitric oxide synthase 2
cofactors and NADPH oxidase components.68 IFN-γ can also promote
an immunosuppressive phenotype by synergising with TGF-β to
amplify Foxp3 expression by CD4+ T cells and enhance Treg cell
differentiation.68 However, prolonged IFN-γ exposure in IFN-γ-over-
expressing mice reduced HCC in DEN-induced HCC model as a
result of enhancing hepatocyte apoptosis.69
Tumour necrosis factor. Hepatic TNF is produced by KCs, mono-
cytes, DCs, B cells and Th1 and Th17 cells. TNF has pleiotropic roles in
immune responses and its effects may depend upon the context,
amount of TNF present and the involvement of either or both TNF
receptors, which often display disparate and opposing roles.70 The
effect of hepatic TNF exposure on immune responses is relatively
unexplored. Acute TNF signalling via the TNF receptors 1 and 2
results in apoptosis or inflammation, respectively. Chronic TNF
exposure in primary sclerosing cholangitis patients, though, promotes
immunosuppression with reduced T-cell proliferation and cytotoxic
T-cell activity.71 The immunosuppression may be due to TNF-induced
nuclear factor-κB-mediated upregulation of CD4+ T-cell expression of
PD-1 as demonstrated in chronic LCMV infection of neonatal mice.72
SUBVERSION OF THE IMMUNE SYSTEM DURING HCC
DEVELOPMENT
The immune system can prevent cancer by protecting against viral
infection, reducing inflammation and/or eliminating tumour cells as a
result of recognition of tumour antigens.9 Below we will discuss how
hepatic immune surveillance is subverted to promote chronic viral
infection and inflammation, both of which can amplify liver cancer
development. We also examine how hepatic tumorigenic cells can
avoid elimination by the immune system, resulting in HCC
progression.
Viral-induced chronic liver disease
Globally, HBV and HCV are the leading viral risk factors for liver
cancer development. As previously discussed, the tolerogenic nature of
the liver invariably means that it does not generate a robust immune
response to acute HBV and HCV infections. Thus HBV and HCV
trigger persistent and chronic inflammatory infections where CD4+
helper T-cell function is impaired, numbers of exhausted CD8+
cytotoxic T cells with suppressed IL-2, TNF and IFN-γ secretion are
reduced and NK cell dysfunction is observed.73
The importance of the CD4+ T helper cells in HBV and HCV
clearance has been highlighted in the chimpanzee model. In a study by
Greyer et al.,29 CD4+ T-cell depletion prior to HBV infection or HCV
reinfection gave rise to persistent infection due to reduced responses
by the integral CD8+ cytotoxic T cells.74 Naive CD8+ T cells are
‘primed’ by CD4+ T cell-induced DC production of IL-15 and
differentiate into cytotoxic T cells.29 Interestingly, though, there are
some patients whose HCV-specific T cells are only weakly primed
during the acute infection phase.75 Hepatitis C-infected patients also
have increased numbers of CD4+ Treg cells, possibly as a result of the
HCV core protein inducing a Treg-like phenotype expressing the Treg
transcription factor Foxp3, together with immunosuppressive IL-10.76
The mechanisms by which CD8+ T cells become exhausted and/or
deleted during viral infection are not completely understood. How-
ever, there are several mechanisms in addition to CD4+ T-cell
dysfunction that may result in CD8+ T-cell exhaustion. First,
prolonged exposure to viral antigen increases TCR signalling. Hepatitis
B and C viruses may also downregulate TCR signalling by reducing
expression of the TCR-associated signalling molecule, CD3ζ, leading
to reduced downstream signalling.77,78 Expression of the
co-stimulatory molecule CD28, is reduced in HBV- and HCV-
infected patients, leading to reduced effectiveness of TCR
signalling.77,78 On the contrary, expression of co-inhibitory molecules,
including PD-1 and Tim-3, are elevated on virus-specific CD8+ T cells
in response to HBV and HCV infection.74 Treatment of HCV-specific
cytotoxic T-cell clones with the Tim-3 ligand, galectin-9, induced
apoptosis of the T cells.79 Tim-3 gene polymorphisms have been
linked to enhanced HBV surface antigen seroclearance.80 Hepatocyte
expression levels of PD-1’s ligand, PD-L1, are also significantly
elevated in response to HBV and HCV infection and may also
contribute to the reduced T-cell function. However, as hepatocyte-
expressed PD-L1 levels are also increased in autoimmune disease,81 it
has been speculated that this may be a result of elevated
inflammation.74
Expression of galectin-9, the ligand for Tim-3, is upregulated on
KCs and monocytes by HCV and induces expansion of CD4+ Tregs in
a TGF-β-dependent manner.79 Hepatitis C virus also downregulates
monocyte production of IL-12 as a result of increasing Tim-3
expression.82 As discussed previously, IL-12 promotes increased
CD4+ Th1 cell numbers.
Non-viral-induced chronic liver disease
The risk of liver cancer is also increased in non-viral pathologies
induced by alcohol and non-alcoholic steatohepatitis. Common
features of these pathologies are fat deposition, chronic inflammation
and elevated TNF, together with persistent injury. Chronic exposure of
T cells to TNF downregulates CD3ζ-chain protein expression and
results in reduced cell surface TCR complex and associated T-cell
hyporesponsiveness as seen in chronic inflammation.83
Liver cancer may also be promoted in these pathologies by the free
fatty acid, linoleic acid. Linoleic acid induces selective global CD4+
T-cell apoptosis as a result of increased mitochondrial oxidative stress,
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and CD4+ T-cell depletion promotes liver cancer in inducible liver-
specific MYC oncogenic transgenic mice fed a methionine and
choline-deficient diet.84 CD4+ T cells may attenuate liver cancer
development by promoting CD8+ cytotoxic T-cell activity against
tumour antigens. Another possible mechanism is that CD4+ T cells are
involved in the resolution of inflammation as TGF-β promotes Th17
T-cell trans-differentiation into Treg cells during inflammation
resolution.85
The contribution of immune checkpoint signalling to the develop-
ment of alcohol- and non-alcohol-induced chronic liver disease is
relatively unexplored to date. PD-1 protein expression is elevated on
CD4+ T cells in alcohol-related cirrhosis and further elevated by
chronic systemic endotoxin in acute alcoholic hepatitis patients in the
first reported investigation of immune checkpoint molecules in non-
viral liver disease.86 Tim-3 is also upregulated in acute alcoholic
hepatitis but not alcohol-related cirrhosis. Ethanol and endotoxin also
promote enhanced PD-1 expression on CD4+ and CD8+ T cells, and
Tregs cells in vitro. However, the effect of elevated PD-1 and Tim-3 on
T-cell exhaustion was not examined in the study. PD-1, though,
promotes inflammation with increased Th17 cell and neutrophil
numbers resulting in enhanced hepatic injury in the murine bile duct
ligation model.87
Hepatocellular carcinoma
Immune surveillance of HCC is subverted by the hepatic cytokine and
immune environment as well as the tumour cells present. Levels of
immunosuppressive cytokines IL-10 and TGF-β are upregulated in
HCC patients at the same time as pro-inflammatory IFN-γ levels are
downregulated.88 An increased percentage of circulating and tumour-
infiltrating CD8+ T cells express PD-1 while tumour cells and tumour-
associated monocytes and neutrophils express upregulated PD-L1 and
CD47 levels in HCC patients.89–92 The numbers of myeloid-derived
suppressor cells are also elevated in HCC patients.88,93 Furthermore,
activation of the c-Myc oncogene switches on PD-L1 and CD47
expression in hepatocytes,94 raising the possibility that oncogenes may
directly regulate PD-L1 levels to subvert surveillance. Nonetheless, the
elevated PD-L1:PD-1 interactions reduce CD4+ and CD8+ T-cell
numbers and function, which subsequently attenuates immune
surveillance. A novel PD-1-expressing B-cell subset whose numbers
correlate with disease stage as well as early recurrence has also recently
been identified in HCC.95 The PD-1hi B cells produce IL-10 in
response to PD-1:PD-L1 interaction and so consequently reduce CD8+
cytotoxic T-cell function. Thus the combined actions of cytokines in
the tumour environment significantly reduce immune surveillance,
allowing HCC to avoid eradication.
IMMUNE CHECKPOINT INHIBITOR THERAPY AND HCC
DEVELOPMENT
It is apparent that immune evasion contributes to both early and later
stages of HCC development. Immune-based monoclonal antibody
therapy has become an attractive alternative to pursue in light of the
recent promising outcomes from trials that involve immune check-
point inhibitors in solid tumour cancer therapy. However, the use of
these therapies in treatment at various stages of HCC development is
in its infancy. We will discuss how the monoclonal antibody therapy
has been used at various stages of HCC development to reduce
incidence, from both preclinical and clinical perspectives.
Immunotherapy in viral-induced chronic liver disease
Immunotherapeutic monoclonal antibody treatment of chronic HBV
and HCV infection to reverse T-cell exhaustion is relatively
unexplored. PD-L1-blockade enhanced IFN-γ production by CD8+
T cells adoptively transferred to HBV transgenic mice and also
restored IFN-γ production by CD8+ T cells and viral clearance in
the HCV core murine model.96 In vitro blocking of PD-L1 on HBV
patient T cells enhanced both CD4+ and CD8+ T-cell production of
IFN-γ.97 Likewise, in vitro blockade of Tim-3 on T cells isolated from
HBV and HCV patients restores virus-specific CD8+ T-cell cytolytic
responses, including IFN-γ expression and T-cell proliferation.98,99
Despite these promising in vitro and in vivo results, treating HCV in
non-human primates by PD-1-blockade led to mixed results with only
one out of three chimpanzees attaining HCV suppression.100 However,
improved outcomes may be achieved by combining the therapy with
other immune interventions.
Immunotherapy in non-viral-induced chronic liver disease
Immune checkpoint inhibitors have not been directly used to modify
chronic inflammation in non-viral chronic liver disease to date.
Instead, they have been used to enhance antibacterial immunity in
alcoholic hepatitis. In vitro blockade of PD-1 and Tim-3 enhanced
IFN-γ and reduced IL-10 production by peripheral blood mono-
nuclear cells and increased neutrophil phagocytic capacity and
Escherichia coli-stimulated oxidative burst.86
Immunotherapy in HCC
Sorafenib, a receptor tyrosine kinase small-molecule inhibitor, is
currently the gold standard and the only systemic therapy approved
for treatment of unresectable advanced HCC, prolonging survival
from 4.2 to 6.5 months in the Asia-Pacific study and from 7.9 to
10.7 months in the SHARP study.101 The differences in outcomes
from the Asia-Pacific and SHARP studies may relate to the disease
initiator, with HBV-related HCC accounting for 73% of patients in the
Asia-Pacific study compared with 15.5% in the SHARP study. Patients
with HCV-related HCC had the greatest benefit with sorafenib
treatment prolonging survival from 7.4 to 14.0 months, suggesting
its efficacy may depend on the underlying HCC aetiology.101 The
modest survival benefit afforded by sorafenib may be partially derived
via beneficial immune modulation, as discussed below, suggesting that
combining sorafenib with other immune therapies may be beneficial
in the treatment of HCC.
Sorafenib regulates hepatic immunity. Specifically, sorafenib blocks
signalling via vascular endothelial growth factor receptor, platelet-
derived growth factor receptor and C-Raf.102–104 Less well known is
the ability of sorafenib to block colony-stimulating factor-1 receptor
activity, which is required for survival, proliferation and differentiation
of monocytes.105 A number of in vitro and in vivo studies have now
reported that sorafenib also stimulates the immune system. Sorafenib
directly upregulates IL-2 secretion by peripheral blood CD4+ Tregs
isolated from HCC patients.106 Sorafenib also inhibited the suppressive
properties and proliferation of CD4+ Tregs as well as enhanced their
apoptosis in a preclinical orthotopic HCC model.107 This was not due
to the reduction in tumour burden, as sorafenib also reduced CD4+
Tregs numbers in tumour-free mice. Further, sorafenib moderated the
number of PD-1-expressing CD8+ T cells. Finally, sorafenib inhibited
the activity of the disintegrin and metalloprotease member ADAM-9
to reduce MHC-1-related chain A shedding from tumour cells and
enhanced NK cell activity.108 Hence, it is apparent that sorafenib may
increase overall survival via immune effects as well as by the more
widely known effects of reducing angiogenesis, arresting cell cycle and
inducing apoptosis.
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Immune checkpoint inhibitors. A recent study showed that anti-PD-1
therapy was more effective in non-small-cell lung cancer that had a
higher nonsynonymous somatic tumour mutation burden.109 In general,
tumour mutation rates are higher when an environmental mutagen is
involved such as ultraviolet radiation in melanoma or cigarette smoke in
lung cancer. Early studies in HCC suggest that tumour mutation burden
is higher in melanoma and lung cancer but may depend upon the
aetiology.110–112 Importantly and similar to melanoma and lung cancer,
HCC does not appear to have an ‘oncogene addiction’.113 Thus it is
reasonable to suggest immune checkpoint inhibitors as promising HCC
treatments. Below, we examine the preclinical and clinical studies that
have been reported thus far.
As discussed previously, expression of PD-1 and CD47 are upregu-
lated in HCC. Anti-murine PD-1 antibody monotherapy reduced
tumour size of the HCA1 orthotopic tumour model by approximately
50% in preclinical studies. However, the same anti-PD-1 antibody
reduced tumour size by only 20% in mammalian sterile 20-like 1
(Mst1− /−Mst2F/−) mice in which hepatocarcinogenesis was induced by
carbon tetrachloride. Eighteen out of the 41 advanced HCC patients with
Child-Pugh scoreoB7 completed a 2-year Phase-I/II clinical safety trial
of the PD-1 inhibitor, nivolumab (CheckMate 040; ClinicalTrials.gov
number NCT01658878), although the dose cycle was not reported.114
Two patients had a complete response, while treatment of 23 patients
was discontinued as a result of disease progression. Only two patients
were discontinued owing to drug-related adverse events. This trial was
extended to include a dose expansion arm of 3 mg kg−1 every 2 weeks in
214 patients.115 Complete response was achieved in three patients while
partial response was achieved in 39 patients and disease was stable in a
further 96 patients.115
The expression of CTLA-4 has not been examined in HCC and no
preclinical studies involving CTLA4 blockade in HCC have been
reported. Notwithstanding, a Phase II clinical trial blocking CTLA4
with a monoclonal antibody has been carried out in 21 patients with
unresectable HCC of Child-Pugh class A or B (Clinicaltrials.gov
number NCT01008358).116 Each patient received at least two treat-
ment cycles of 90 days. Seventeen patients were evaluated for tumour
response, with no complete responses and three patients with partial
response that lasted for up to 15.8 months. Disease was stabilised in a
further 10 patients with half stabilised for 46 months.116
CD47 is an innate immune checkpoint that binds to signal
regulatory protein-α on monocytes, macrophages and DCs. CD47
inhibits phagocytic activity of these APCs by acting as a ‘don’t eat me’
signal. Antibody neutralisation of CD47 enhances phagocytosis of
tumour cells and increases the durability of T-cell immune inhibitory
therapy. Preclinical studies in various HCC xenograft models have
mostly shown that monoclonal antibody inhibition of CD47 sup-
presses tumour growth.117 Further, CD47 blockade sensitises Huh7/
MHCC-97L tumour cells to the chemotherapeutic drugs doxorubicin
and cisplatin by increasing macrophage phagocytosis in in vivo murine
zenografts.118 However, to the best of our knowledge, no clinical trials
targeting CD47 in HCC have been initiated.
Second-generation immunotherapies against negative regulators of
T-cell activation, including Tim-3 and Lag-3, are in the relatively early
stages of clinical development for advanced solid tumours. Patients are
currently being recruited for Phase I/IIa dose escalation and cohort
expansion trials for Tim-3 and Lag-3 (ClinicalTrials.gov
NCT02817633 and NCT01968109, respectively). The roles of Tim-3
and Lag-3 are relatively unexplored in HCC development. Tim-3 is
expressed on an increased percentage of CD4+ and CD8+ T cells in
HBV-induced HCC compared with the surrounding tissue and
predicted a poor prognosis.119 Further, Tim-3 expression on
tumour-associated macrophages in HBV-induced HCC stimulated
tumour-promoting IL-6 production.120 Similarly, Lag-3 is also
expressed on an increased percentage of CD8+ T cells in HBV-
induced HCC and correlates with impaired HBV-specific CD8+
cytotoxicity in HCC patients.121 However, it remains to be seen how
successful these second-generation immunotherapies will be in
general.
Immune checkpoint molecules have critical roles in fine-tuning the
immune system to maintain self-tolerance. As such, patients may
develop immune-related adverse events ranging from common but
mild symptoms such as fatique, nausea and skin rash to the severe but
much less common such as hypothyroidism and the neurological
conditions, Guillain–Barre syndrome and myasthenia gravis.122 Skin
rash (65%), fatigue (55%) and diarrhoea (30%) were the most
commonly reported immune-related adverse events in HCC patients
receiving anti-CTLA-4 treatment.116 Hypothyroidism was only
observed in 1 out of the 20 patients who underwent the anti-CTLA-4
treatment.116 Anti-PD-1 treatment of HCC patients resulted in less
immune-related adverse events, with skin rash (23%), pruritis (19%)
and diarrhoea (10%) most commonly reported.115
Another possible immune-related side effect of immune checkpoint
inhibitor reactivation of T-cell cytotoxicity is an increase in hepatic
damage. Anti-PD-1 (10 mg kg− 1) treatment in a proof-of-concept
study (NCT00703469) in 10 patients resulted in one Grade 4 elevation
(48 upper limits of normal) of serum alanine transaminase, although
other indicators of hepatic function such as bilirubin and the
international normalised ratio (that is, blood-clotting test) did not
change. The elevated serum alanine transaminase coincided with the
onset of a four-log reduction in HCV load and resolved without
intervention.123 Anti-CTLA-4 treatment resulted in a Grade 3 eleva-
tion of serum transaminases after the first dose in more than half of
the HCV-induced HCC patients but was not associated with a decline
in liver function.116 Moreover, anti-CTLA-4 treatment also reduced
the HCV load and tended to increase the numbers of IFN-γ-
producing lymphocytes in the study by Sangro et al.116 Regardless,
blockade of both CTLA-4 and PD-1 were concluded to be safe in
treatment of HCC regardless of viral status.115,116
Sorafenib and immune checkpoint inhibitors. As development of
resistance is often the long-term response to sorafenib treatment,
combination therapy with immune checkpoint inhibitors has been
explored in preclinical studies. Sorafenib-resistant tumour cells derived
from patient xenografts had elevated CD47 levels and CD47 blockade
reduced their proliferation.118 PD-1 blockade, though, did not
enhance sorafenib-reduced tumour growth in the orthotopic HCC
implant and Mst-mutant mouse HCC models. However, PD-1
blockade together with inhibition of stromal cell-derived 1α receptor,
C-X-C motif chemokine receptor 4, did significantly further reduce
tumour growth in these two models.124 These preclinical data suggest
that immune checkpoint inhibitor therapy combined with sorafenib
may lead to improved outcomes.115 We await the outcome of the
clinical trial combining sorafenib treatment with the anti-PD-1
monoclonal therapy, PDR001 (ClinicalTrials.gov number
NCT02988440). Clinical trials of other currently approved therapies
combined with immune checkpoint inhibitors are listed in Table 1.
CONCLUSION
The role of the immune system in liver pathologies leading to HCC is
complex and significant. The failure of many new drugs targeting
HCC in phase III trials mandates that new and different approaches
are more thoroughly explored. Immune checkpoint inhibitor therapy
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to stimulate the immune system has been demonstrated to be safe in
HCC patients in the limited clinical data available. While showing
promise, efficacy of the checkpoint inhibitors has been somewhat
limited. The majority of preclinical studies of immune checkpoint
inhibitors in HCC to date have used orthotopic or xenograft models to
validate their efficacy. There is currently a profound lack of under-
standing of how the immune system controls the various stages of
HCC development. Comprehensive expression profiling of checkpoint
inhibitors together with detailed studies of how the immune system
dampens HCC development during disease progression in models of
different aetiologies that naturally develop HCC, while mimicking
human disease need to be undertaken to realise the clinical potential of
immune checkpoint inhibitor therapy. Importantly, these studies
would enable the determination of clinical aetiologies and/or stage(s)
for which the intervention will be most effective.
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Table 1 Clinical trials involving immune checkpoint inhibitors
Target Antibody Phase Trial ID Sponsor Combination treatment Study population Status Results
CTLA-4 CP-675,206 2 NCT01008358 Clinica Universidad de
Navarra
NA Patients with HCV-induced HCC not
amenable to other therapies
Completed 115
Tremelimumab 1 NCT01853618 National Cancer
Institute
TACE, radiofrequency abla-
tion, SBRT or
chemoembolisation
Patients with advanced liver cancer Ongoing/
not
recruiting
NA
Tremelimumab 1/2 NCT02821754 National Cancer
Institute
Durvalumab and TACE, radio-
frequency ablation, SBRT or
chemoembolisation
Patients with advanced liver cancer Recruiting NA
PD-1 Nivolumab 1/2 NCT01658878 Bristol-Myers Squibb &
Ono Pharmaceutical
Co. Ltd.
Part 1—safety; Part 2—com-
parison with sorafenib; Part 3
—combination with Ipillimu-
mab (CTLA-4)
Parts 1, 2—patients with uninfected
HCC, HCV-infected HCC patients, HBV-
infected HCC patients; Part 3—patients
with advanced HCC
Recruiting 114
Nivolumab 3 NCT02576509 Bristol-Myers Squibb &
Ono Pharmaceutical
Co. Ltd.
Comparison with sorafenib Patients with advanced HCC Recruiting NA
Nivolumab 1 NCT02837029 Northwestern Univer-
sity, Bristol-Myers
Squibb and National
Cancer Institute
Y90 glass microspheres Patients with stages IIIA, IIIB, IIIC, IVA
and IVB HCC
Recruiting NA
Nivolumab 1/2 NCT02859324 Celgene CC-122 (pleitropic pathway
modifier)
Patients with unresectable HCC Recruiting NA
Nivolumab 2 NCT03033446 National Cancer Cen-
tre, Singapore
Y90 radioembolisation Asian patients with advanced HCC Recruiting NA
Nivolumab 1/2a NCT03071094 Transgene Pexa-Vec (JX-594 oncolytic
virus)
Patients with advanced liver cancer Not yet
recruiting
NA
Nivolumab 1 NCT03143270 Memorial Sloane Ket-
tering Cancer Center
Drug eluting bead transarterial
chemoembolisation
Patients with advanced HCC Recruiting NA
Pembrolizumab 2 NCT02702414 Merck Sharp & Dohme
Corp.
NA Patients with previously systemically
treated HCC
Ongoing/
not
recruiting
NA
PDR001 1/2 NCT02795429 Novartis
Pharmaceuticals
INC280 (c-Met) Adult patients with advanced HCC Recruiting NA
PDR001 1b NCT02988440 Novartis
Pharmaceuticals
Sorafenib Adult patients with advanced HCC Recruiting NA
SHR-1210 1/2 NCT02942329 The Affiliated Hospital
of the Chinese Acad-
emy of Military Medical
Sciences
Apatinib (VEGFRII) Patients with HCC or gastric cancer Recruiting NA
SHR-1210 2/3 NCT02989922 Jiangsu HengRui Med-
icine Co., Ltd
NA Patients with non-resectable HCC who
failed or did not tolerate prior systemic
treatment
Recruiting NA
Pembrolizumab 1 NCT03099564 Hoosier Cancer
Research Network
Y90 radioembolisation Patients with poor prognosis HCC who are
ineligible for liver transplant or surgical
resection with well-compensated liver
function
Recruiting NA
Abbreviations: CTLA-4, cytotoxic T lymphocyte antigen 4; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NA, not applicable; PD-1, programmed cell death protein-1;
SBRT, stereotactic body radiation therapy; TACE, transarterial chemoembolization; VEGFR, vascular endothelial growth factor receptor.
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